Rebuttal of the pro view: Albuminuria is an appropriate therapeutic target in patients with CKD

Clinical Journal of the American Society of Nephrology

Volumn 10, Issue 6, 2015, Pages 1095-1098

  Fried, Linda F ^a   Lewis, Julia ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SERUM ALBUMIN; URINARY TRACT AGENT;

ALBUMINURIA; ARTICLE; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; HYPERLIPIDEMIA; META ANALYSIS (TOPIC); OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PREDICTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT; SCORING SYSTEM; DRUG EFFECTS; KIDNEY; METABOLISM; RENAL INSUFFICIENCY, CHRONIC;

ALBUMINURIA; HUMANS; KIDNEY; RENAL INSUFFICIENCY, CHRONIC; SERUM ALBUMIN; UROLOGICAL AGENTS;

EID: 84930423029     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.01610215     Document Type: Article

References (13)

1. Imai E, Haneda M, Chan JCN, Yamasaki T, Kobayashi F, Ito S, Makino H: Reduction and residual proteinuria are therapeutic targets in type 2 diabetes with overt nephropathy: A post hoc analysis (ORIENT-proteinuria). Nephrol Dial Transplant 28: 2526-2534, 2013
2. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Kidney Int 65: 2309-2320, 2004
3. Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, DuckworthW, LeeheyDJ,McCullough PA,O'Connor T, Palevsky PM, Reilly RF, Seliger SL, Warren SR, Watnick S, Peduzzi P, Guarino P; VA NEPHRON-D Investigators: Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 369: 1892-1903, 2013
4. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsärinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S; ONTARGET Investigators: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 372: 547-553, 2008
5. ParvingHH, Brenner BM, McMurray JJ, de ZeeuwD, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA; ALTITUDE Investigators: Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 367: 2204-2213, 2012
6. Sakata Y, Shiba N, Takahashi J, Miyata S, Nochioka K, Miura M, Takada T, Saga C, Shinozaki T, Sugi M, Nakagawa M, Sekiguchi N, Komaru T, Kato A, Fukuchi M, Nozaki E, Hiramoto T, Inoue K, Goto T, Ohe M, Tamaki K, Ibayashi S, Ishide N, Maruyama Y, Tsuji I, ShimokawaH; SUPPORT Trial Investigators: Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: The Supplemental Benefit of an Angiotensin Receptor Blocker in Hypertensive Patients with Stable Heart Failure Using Olmesartan (SUPPORT) trial [published online ahead of print January 30, 2015]. Eur Heart J doi: 10.1093/eurheartj/ehu504
7. Lassere MN: The Biomarker-Surrogacy Evaluation Schema: A review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogate endpoints. StatMethods Med Res 17: 303-340, 2008
8. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group: KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl 2: 139-274, 2012
9. Lambers Heerspink HJ, Kröpelin TF, Hoekman J, de Zeeuw D; Reducing Albuminuria as Surrogate Endpoint (REASSURE) Consortium: Drug-induced reduction in albuminuria is associated with subsequent renoprotection: A meta-analysis [published online ahead of print November 24, 2014]. J Am Soc Nephrol doi:10.1681/ASN.2014070688
10. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001
11. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860, 2001
12. Bakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K, Velazquez EJ, Staikos-Byrne L, Kelly RY, Shi V, Chiang YT,Weber MA; ACCOMPLISH Trial investigators: Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): A prespecified secondary analysis of a randomised controlled trial. Lancet 375: 1173-1181, 2010
13. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators: Aliskiren combined with losartan in type 2 diabetes and nephropathy. NEngl JMed 358: 2433-2446, 2008